HRP20241716T1 - Postupci liječenja promjena u ponašanju - Google Patents
Postupci liječenja promjena u ponašanju Download PDFInfo
- Publication number
- HRP20241716T1 HRP20241716T1 HRP20241716TT HRP20241716T HRP20241716T1 HR P20241716 T1 HRP20241716 T1 HR P20241716T1 HR P20241716T T HRP20241716T T HR P20241716TT HR P20241716 T HRP20241716 T HR P20241716T HR P20241716 T1 HRP20241716 T1 HR P20241716T1
- Authority
- HR
- Croatia
- Prior art keywords
- use according
- pharmaceutical composition
- compound
- behavioral change
- aggression
- Prior art date
Links
- 230000003542 behavioural effect Effects 0.000 title claims 7
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 5
- 229940123628 Lysine (K)-specific demethylase 1A inhibitor Drugs 0.000 claims 4
- 206010041243 Social avoidant behaviour Diseases 0.000 claims 3
- 230000016571 aggressive behavior Effects 0.000 claims 3
- XBBRLCXCBCZIOI-DLBZAZTESA-N vafidemstat Chemical compound O1C(N)=NN=C1CN[C@H]1[C@H](C=2C=CC(OCC=3C=CC=CC=3)=CC=2)C1 XBBRLCXCBCZIOI-DLBZAZTESA-N 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Peptides Or Proteins (AREA)
Claims (7)
1. Inhibitor KDM1A koji je 5-((((1R,2S)-2-(4-(benziloksi)fenil)ciklopropil)amino)metil)-1,3,4-oksadiazol-2-amin, ili farmaceutski njegova prihvatljiva sol ili solvat, za upotrebu u liječenju promjene ponašanja, pri čemu je promjena ponašanja socijalno povlačenje ili agresivnost.
2. Farmaceutski pripravak za upotrebu u liječenju promjene ponašanja, pri čemu je promjena ponašanja socijalno povlačenje ili agresivnost, pri čemu farmaceutski pripravak sadrži inhibitor KDM1A koji je 5-((((1R,2S)-2-(4-(benziloksi)fenil)ciklopropil)amino)metil)-1,3,4-oksadiazol-2-amin, ili njegova farmaceutski prihvatljiva sol ili solvat, i jednu ili više farmaceutski prihvatljivih pomoćnih tvari ili nosača.
3. Spoj za upotrebu prema zahtjevu 1 ili farmaceutski pripravak za upotrebu prema zahtjevu 2, naznačen time što je promjena ponašanja socijalno povlačenje.
4. Spoj za upotrebu prema zahtjevu 1 ili farmaceutski pripravak za upotrebu prema zahtjevu 2, naznačen time što je promjena ponašanja agresivnost.
5. Spoj za upotrebu prema bilo kojem od zahtjeva 1, 3 ili 4 ili farmaceutski pripravak za upotrebu prema bilo kojem od zahtjeva 2 do 4, pri čemu je pacijent kojeg treba liječiti čovjek.
6. Spoj za upotrebu prema bilo kojem od zahtjeva 1 ili 3 do 5 ili farmaceutski pripravak za upotrebu prema bilo kojem od zahtjeva 2 do 5, naznačen time što je inhibitor KDM1A 5-((((1R,2S)-2-(4-(benziloksi)fenil)ciklopropil)amino)metil)-1,3,4-oksadiazol-2-amin.
7. Spoj za upotrebu prema bilo kojem od zahtjeva 1 ili 3 do 6 ili farmaceutski pripravak za upotrebu prema bilo kojem od zahtjeva 2 do 6, naznačen time što se inhibitor KDM1A ili farmaceutski pripravak primjenjuje oralno.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17382545 | 2017-08-03 | ||
| EP17382544 | 2017-08-03 | ||
| EP18382299 | 2018-04-30 | ||
| PCT/EP2018/071120 WO2019025588A1 (en) | 2017-08-03 | 2018-08-03 | METHODS OF TREATING ALTERATIONS IN BEHAVIOR |
| EP18748921.6A EP3661510B1 (en) | 2017-08-03 | 2018-08-03 | Methods of treating behavior alterations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20241716T1 true HRP20241716T1 (hr) | 2025-02-14 |
Family
ID=63077881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20241716TT HRP20241716T1 (hr) | 2017-08-03 | 2018-08-03 | Postupci liječenja promjena u ponašanju |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20200323828A1 (hr) |
| EP (2) | EP3661510B1 (hr) |
| JP (2) | JP2020529995A (hr) |
| KR (2) | KR20240122847A (hr) |
| CN (1) | CN110996949A (hr) |
| AU (2) | AU2018309372B2 (hr) |
| BR (1) | BR112020000827A2 (hr) |
| CA (1) | CA3071804A1 (hr) |
| DK (1) | DK3661510T3 (hr) |
| ES (1) | ES3001085T3 (hr) |
| FI (1) | FI3661510T3 (hr) |
| HR (1) | HRP20241716T1 (hr) |
| HU (1) | HUE069697T2 (hr) |
| IL (1) | IL272092A (hr) |
| LT (1) | LT3661510T (hr) |
| MX (2) | MX2020001323A (hr) |
| MY (1) | MY204406A (hr) |
| PH (1) | PH12020500211A1 (hr) |
| PL (1) | PL3661510T3 (hr) |
| RS (1) | RS66336B1 (hr) |
| SG (1) | SG11202000077RA (hr) |
| SI (1) | SI3661510T1 (hr) |
| WO (1) | WO2019025588A1 (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3017408A1 (en) | 2016-03-15 | 2017-09-21 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors for the treatment of hematological malignancies |
| MX2021011254A (es) * | 2019-03-20 | 2021-10-01 | Oryzon Genomics Sa | Metodos de tratamiento del trastorno por deficit de atencion e hiperactividad. |
| KR20210141933A (ko) * | 2019-03-20 | 2021-11-23 | 오리존 지노믹스 에스.에이. | 경계성 인격 장애의 치료 방법 |
| CN114615979A (zh) * | 2019-09-03 | 2022-06-10 | 奥莱松基因组股份有限公司 | 用于治疗孤独症谱系障碍的伐菲德司他 |
| CN114502561B (zh) * | 2019-09-29 | 2023-12-26 | 南昌弘益药业有限公司 | Lsd1抑制剂 |
| CN118604352A (zh) * | 2024-05-22 | 2024-09-06 | 暨南大学 | Vps13a表达促进剂在制备用于抑郁症诊断和治疗药物中的应用 |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| CN101410367A (zh) | 2005-08-10 | 2009-04-15 | 约翰·霍普金斯大学 | 多胺用在抗寄生虫与抗癌治疗学以及作为赖氨酸-特异性脱甲基酶抑制剂 |
| WO2008127734A2 (en) | 2007-04-13 | 2008-10-23 | The Johns Hopkins University | Lysine-specific demethylase inhibitors |
| WO2010043721A1 (en) | 2008-10-17 | 2010-04-22 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
| WO2010084160A1 (en) | 2009-01-21 | 2010-07-29 | Oryzon Genomics S.A. | Phenylcyclopropylamine derivatives and their medical use |
| US8389580B2 (en) | 2009-06-02 | 2013-03-05 | Duke University | Arylcyclopropylamines and methods of use |
| JPWO2010143582A1 (ja) | 2009-06-11 | 2012-11-22 | 公立大学法人名古屋市立大学 | フェニルシクロプロピルアミン誘導体及びｌｓｄ１阻害剤 |
| EP2467359A4 (en) | 2009-08-18 | 2013-01-09 | Univ Johns Hopkins | (BIS-) UREA- AND (BIS-) THIOMINE COMPOUNDS AS EPIGENE MODULATORS OF THE LYSINE-SPECIFIC DEMETHYLASE 1 AND METHODS OF DISEASE TREATMENT THEREWITH |
| CA2812683C (en) | 2009-09-25 | 2017-10-10 | Oryzon Genomics S.A. | Lysine specific demethylase-1 inhibitors and their use |
| EP2486002B1 (en) | 2009-10-09 | 2019-03-27 | Oryzon Genomics, S.A. | Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use |
| ES2607081T3 (es) | 2010-04-19 | 2017-03-29 | Oryzon Genomics, S.A. | Inhibidores de desmetilasa específica de lisina-1 y su uso |
| WO2011131576A1 (en) | 2010-04-20 | 2011-10-27 | Università Degli Studi Di Roma "La Sapienza" | Tranylcypromine derivatives as inhibitors of histone demethylase lsd1 and/or lsd2 |
| BR112013002164B1 (pt) * | 2010-07-29 | 2021-11-09 | Oryzon Genomics S.A. | Inibidores de desmetilase à base de arilciclopropilamina de lsd1, seus usos, e composição farmacêutica |
| EP2598480B1 (en) | 2010-07-29 | 2019-04-24 | Oryzon Genomics, S.A. | Cyclopropylamine derivatives useful as lsd1 inhibitors |
| WO2012034116A2 (en) | 2010-09-10 | 2012-03-15 | The Johns Hopkins University | Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders |
| US9061966B2 (en) | 2010-10-08 | 2015-06-23 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
| WO2012071469A2 (en) | 2010-11-23 | 2012-05-31 | Nevada Cancer Institute | Histone demethylase inhibitors and uses thereof for treatment o f cancer |
| WO2012135113A2 (en) | 2011-03-25 | 2012-10-04 | Glaxosmithkline Llc | Cyclopropylamines as lsd1 inhibitors |
| WO2013022047A1 (ja) | 2011-08-09 | 2013-02-14 | 武田薬品工業株式会社 | シクロプロパンアミン化合物 |
| BR112014003382B1 (pt) | 2011-08-15 | 2022-03-15 | University Of Utah Research Foundation | Análogos de (e)-n-(1-feniletilideno) benzo-hidrazida substituída como inibidores de histona desmetilase e composições farmacêuticas compreendendo-os |
| US9289415B2 (en) | 2011-09-01 | 2016-03-22 | The Brigham And Women's Hospital, Inc. | Treatment of cancer |
| RS58475B1 (sr) | 2011-10-20 | 2019-04-30 | Oryzon Genomics Sa | Jedinjenja (hetero)aril ciklopropilamina kao lsd1 inhibitori |
| EP2768805B1 (en) | 2011-10-20 | 2020-03-25 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
| US9751885B2 (en) | 2012-10-12 | 2017-09-05 | Takeda Pharmaceutical Company Limited | Cyclopropanamine compound and use thereof |
| WO2014084298A1 (ja) | 2012-11-28 | 2014-06-05 | 京都府公立大学法人 | リシン構造を有するｌｓｄ1選択的阻害薬 |
| US9144555B2 (en) | 2012-11-30 | 2015-09-29 | Darlene E. McCord | Hydroxytyrosol and oleuropein compositions for induction of DNA damage, cell death and LSD1 inhibition |
| EP2740474A1 (en) | 2012-12-05 | 2014-06-11 | Instituto Europeo di Oncologia S.r.l. | Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a |
| CN103054869A (zh) | 2013-01-18 | 2013-04-24 | 郑州大学 | 含三唑基的氨基二硫代甲酸酯化合物在制备以lsd1为靶标药物中的应用 |
| WO2014164867A1 (en) | 2013-03-11 | 2014-10-09 | Imago Biosciences | Kdm1a inhibitors for the treatment of disease |
| MX366949B (es) | 2013-06-19 | 2019-07-30 | Univ Utah Res Found | Análogos sustituidos de (e)-n'-(1-feniletiliden)benzohidrazida como inhibidores de histona desmetilasa. |
| CN103319466B (zh) | 2013-07-04 | 2016-03-16 | 郑州大学 | 含香豆素母核的1,2,3-三唑-氨基二硫代甲酸酯化合物、制备方法及其应用 |
| AU2014306149B2 (en) | 2013-08-06 | 2019-09-19 | Imago Biosciences Inc. | KDM1A inhibitors for the treatment of disease |
| US9186391B2 (en) | 2013-08-29 | 2015-11-17 | Musc Foundation For Research Development | Cyclic peptide inhibitors of lysine-specific demethylase 1 |
| WO2015031564A2 (en) | 2013-08-30 | 2015-03-05 | University Of Utah | Substituted-1h-benzo[d]imidazole series compounds as lysine-specfic demethylase 1 (lsd1) inhibitors |
| WO2015089192A1 (en) | 2013-12-11 | 2015-06-18 | Quanticel Pharmaceuticals, Inc. | Inhibitors of lysine specific demethylase-1 |
| WO2015120281A1 (en) | 2014-02-07 | 2015-08-13 | Musc Foundation For Research Development | Aminotriazole- and aminotetrazole-based kdm1a inhibitors as epigenetic modulators |
| SMT201900620T1 (it) | 2014-02-13 | 2020-01-14 | Incyte Corp | Ciclopropilammine come inibitori di lsd1 |
| WO2015123465A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| EP3105219B9 (en) | 2014-02-13 | 2018-10-03 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| WO2015123437A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| JP2017508798A (ja) | 2014-03-07 | 2017-03-30 | ザ ジョンズ ホプキンス ユニバーシティ | ヒストンリジン特異的デメチラーゼ（ｌｓｄ１）およびヒストンデアセチラーゼ（ｈｄａｃ）の阻害剤 |
| CN103893163B (zh) | 2014-03-28 | 2016-02-03 | 中国药科大学 | 2-([1，1′-联苯]-4-基)2-氧代乙基4-((3-氯-4-甲基苯基)氨基)-4-氧代丁酸酯在制备lsd1抑制剂药物中的应用 |
| EP3129369A1 (en) | 2014-04-11 | 2017-02-15 | Takeda Pharmaceutical Company Limited | Cyclopropanamine compound and use thereof |
| CN103961340B (zh) | 2014-04-30 | 2019-06-25 | 南通中国科学院海洋研究所海洋科学与技术研究发展中心 | 一类lsd1抑制剂及其应用 |
| HUE057895T2 (hu) | 2014-05-01 | 2022-06-28 | Celgene Quanticel Res Inc | Lizinspecifikus demetiláz-1 inhibitorai |
| WO2015181380A1 (en) | 2014-05-30 | 2015-12-03 | Ieo - Istituto Europeo Di Oncologia S.R.L. | Cyclopropylamine compounds as histone demethylase inhibitors |
| CN104119280B (zh) | 2014-06-27 | 2016-03-16 | 郑州大学 | 含氨基类脲与端炔结构单元的嘧啶衍生物、制备方法及应用 |
| EA030946B1 (ru) | 2014-06-27 | 2018-10-31 | Селджен Квонтисел Рисёрч, Инк. | Ингибиторы лизин-специфической деметилазы-1 |
| EA201790082A1 (ru) | 2014-07-03 | 2017-08-31 | Селджен Квонтисел Рисёрч, Инк. | Ингибиторы лизин-специфической демитилазы-1 |
| PL3511319T3 (pl) | 2014-07-03 | 2023-09-11 | Celgene Quanticel Research, Inc. | Inhibitory lizyno-specyficznej demetylazy-1 |
| US9695167B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors |
| TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪 |
| TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
| US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
| EP2993175A1 (en) | 2014-09-05 | 2016-03-09 | IEO - Istituto Europeo di Oncologia Srl | Thienopyrroles as histone demethylase inhibitors |
| CN107074787B (zh) | 2014-09-05 | 2020-10-27 | 赛尔基因昆蒂赛尔研究公司 | 赖氨酸特异性脱甲基酶-1的抑制剂 |
| JP6636031B2 (ja) | 2015-01-30 | 2020-01-29 | ジェネンテック， インコーポレイテッド | 治療用化合物およびその使用 |
| RS66458B1 (sr) | 2015-02-12 | 2025-02-28 | Imago Biosciences Inc | Kdm1a inhibitor i njegova primena u terapiji |
| CN106146361A (zh) | 2015-03-16 | 2016-11-23 | 四川大学 | 茚-1-亚基磺酰基苯甲酰肼衍生物及其制备方法和用途 |
| UA122688C2 (uk) | 2015-04-03 | 2020-12-28 | Інсайт Корпорейшн | Гетероциклічні сполуки як інгібітори lsd1 |
| CN106045862B (zh) | 2015-04-10 | 2019-04-23 | 上海迪诺医药科技有限公司 | 环丙胺类螺(杂)环化合物、其药物组合物及应用 |
| US10526287B2 (en) | 2015-04-23 | 2020-01-07 | Constellation Pharmaceuticals, Inc. | LSD1 inhibitors and uses thereof |
| EP3090998A1 (en) | 2015-05-06 | 2016-11-09 | F. Hoffmann-La Roche AG | Solid forms |
| WO2017004519A1 (en) | 2015-07-02 | 2017-01-05 | University Of Utah Research Foundation | Substituted benzohydrazide analogs as histone demethylase inhibitors |
| PH12018500317B1 (en) | 2015-08-12 | 2023-01-11 | Incyte Holdings Corp | Salts of an lsd1 inhibitor |
| RS61404B1 (sr) | 2015-11-05 | 2021-02-26 | Celgene Quanticel Research Inc | Kompozicije koje sadrže inhibitor lizin specifične demetilaze-1 koje imaju pirimidinski prsten i njihova primena u lečenju kancera |
| US10059668B2 (en) | 2015-11-05 | 2018-08-28 | Mirati Therapeutics, Inc. | LSD1 inhibitors |
| US10723742B2 (en) | 2015-11-27 | 2020-07-28 | Taiho Pharmaceutical Co., Ltd. | Biphenyl compound or salt thereof |
| WO2017109061A1 (en) | 2015-12-23 | 2017-06-29 | Ieo - Istituto Europeo Di Oncologia S.R.L. | Spirocyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a |
| EP3397616B1 (en) | 2015-12-29 | 2020-06-10 | Mirati Therapeutics, Inc. | Lsd1 inhibitors |
| EP3397756B1 (en) | 2015-12-30 | 2023-03-08 | Novartis AG | Immune effector cell therapies with enhanced efficacy |
| ES2831832T3 (es) | 2016-03-01 | 2021-06-09 | Novartis Ag | Compuestos de indol ciano-sustituidos y usos de los mismos como inhibidores de LSD1 |
| CN107200706A (zh) | 2016-03-16 | 2017-09-26 | 中国科学院上海药物研究所 | 一类氟取代的环丙胺类化合物及其制备方法、药物组合物和用途 |
| US20170283397A1 (en) | 2016-03-31 | 2017-10-05 | University Of Utah Research Foundation | Substituted 1-h-indol-3-yl-benzamide and 1, 1'-biphenyl analogs as histone demethylase inhibitors |
| WO2017195216A1 (en) | 2016-05-09 | 2017-11-16 | Jubilant Biosys Limited | Cyclopropyl-amide compounds as dual lsd1/hdac inhibitors |
| EP3246330A1 (en) | 2016-05-18 | 2017-11-22 | Istituto Europeo di Oncologia S.r.l. | Imidazoles as histone demethylase inhibitors |
| CN107513068A (zh) | 2016-06-16 | 2017-12-26 | 中国科学院上海药物研究所 | 一种具有fgfr抑制活性的新型化合物及其制备和应用 |
| CN106478639B (zh) | 2016-09-05 | 2018-09-18 | 郑州大学 | 嘧啶并1,2,4–三氮唑类的lsd1抑制剂、其制备方法及应用 |
| CN106432248B (zh) | 2016-09-27 | 2018-11-27 | 郑州大学 | 含嘧啶并三氮唑类lsd1抑制剂、其制备方法及应用 |
| HUE063848T2 (hu) | 2016-10-26 | 2024-02-28 | Constellation Pharmaceuticals Inc | LSD1 gátlók és gyógyászati alkalmazásaik |
| WO2018081342A1 (en) | 2016-10-26 | 2018-05-03 | Constellation Pharmaceuticals, Inc. | Lsd1 inhibitors and uses thereof |
| CN106831489B (zh) | 2017-03-23 | 2018-04-17 | 郑州大学 | 苯环丙胺酰腙类化合物、制备方法及其应用 |
| CN106928235A (zh) | 2017-05-03 | 2017-07-07 | 郑州大学 | 含嘧啶并三氮唑类lsd1抑制剂、其制备方法及应用 |
-
2018
- 2018-08-03 ES ES18748921T patent/ES3001085T3/es active Active
- 2018-08-03 RS RS20241411A patent/RS66336B1/sr unknown
- 2018-08-03 FI FIEP18748921.6T patent/FI3661510T3/fi active
- 2018-08-03 PL PL18748921.6T patent/PL3661510T3/pl unknown
- 2018-08-03 MX MX2020001323A patent/MX2020001323A/es unknown
- 2018-08-03 KR KR1020247023305A patent/KR20240122847A/ko active Pending
- 2018-08-03 CA CA3071804A patent/CA3071804A1/en active Pending
- 2018-08-03 LT LTEPPCT/EP2018/071120T patent/LT3661510T/lt unknown
- 2018-08-03 AU AU2018309372A patent/AU2018309372B2/en active Active
- 2018-08-03 CN CN201880050319.1A patent/CN110996949A/zh active Pending
- 2018-08-03 HU HUE18748921A patent/HUE069697T2/hu unknown
- 2018-08-03 HR HRP20241716TT patent/HRP20241716T1/hr unknown
- 2018-08-03 KR KR1020207006287A patent/KR102685898B1/ko active Active
- 2018-08-03 BR BR112020000827-3A patent/BR112020000827A2/pt unknown
- 2018-08-03 SI SI201831191T patent/SI3661510T1/sl unknown
- 2018-08-03 EP EP18748921.6A patent/EP3661510B1/en active Active
- 2018-08-03 DK DK18748921.6T patent/DK3661510T3/da active
- 2018-08-03 EP EP24205125.8A patent/EP4512473A3/en active Pending
- 2018-08-03 SG SG11202000077RA patent/SG11202000077RA/en unknown
- 2018-08-03 JP JP2020505367A patent/JP2020529995A/ja active Pending
- 2018-08-03 US US16/635,704 patent/US20200323828A1/en not_active Abandoned
- 2018-08-03 WO PCT/EP2018/071120 patent/WO2019025588A1/en active Application Filing
- 2018-08-03 MY MYPI2020000100A patent/MY204406A/en unknown
-
2020
- 2020-01-16 IL IL272092A patent/IL272092A/en unknown
- 2020-01-28 PH PH12020500211A patent/PH12020500211A1/en unknown
- 2020-01-31 MX MX2023009388A patent/MX2023009388A/es unknown
-
2023
- 2023-08-18 US US18/451,897 patent/US20240277673A1/en active Pending
- 2023-08-24 JP JP2023136283A patent/JP2023159354A/ja active Pending
-
2024
- 2024-11-14 AU AU2024264660A patent/AU2024264660A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20241716T1 (hr) | Postupci liječenja promjena u ponašanju | |
| HRP20191957T1 (hr) | Policiklični-karbamoilpiridonski spojevi i njihova farmaceutska upotreba | |
| NI201700101A (es) | Composiciones farmacéuticas que comprenden n - (3, 5 - dimetoxifenil) - n'- (1-metiletil) - n - [3-(1-metil-1h-pirazol-4-il) quinoxalina-6-il]etano-1,2-diamina | |
| JP2020529995A5 (hr) | ||
| HRP20231018T1 (hr) | Terapeutski spojevi korisni za profilaktičko ili terapijsko liječenje hiv virusne infekcije | |
| MX2024010140A (es) | Nuevos metodos. | |
| HRP20191121T1 (hr) | Tretman multiple skleroze | |
| WO2020115555A3 (en) | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia | |
| JP2016508134A5 (hr) | ||
| MX383665B (es) | Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer. | |
| JP2015523407A5 (hr) | ||
| JP2015038135A5 (hr) | ||
| HRP20241221T1 (hr) | POLICIKLIČNI KARBAMOILPIRIDONSKI DERIVATI ZA LIJEČENJE HIV-a | |
| WO2016109217A3 (en) | Btk inhibitors | |
| SA519410865B1 (ar) | مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه | |
| JP2015537009A5 (hr) | ||
| AR099299A1 (es) | Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares | |
| HK1252411A1 (zh) | 磷脂酰肌醇3-激酶抑制劑的給藥方案 | |
| JP2015516452A5 (hr) | ||
| HRP20191434T1 (hr) | Liječenje eritromelalgije | |
| CO2018009543A2 (es) | Composición farmacéutica de liberación prolongada que comprende cisteamina o sal de la misma | |
| CR20160172A (es) | Ácido {4-[5-(3-cloro-fenoxi)-oxazolo[5,4-d]pirimidin-2-il]-2,6-dimetil-fenoxi}acético para su uso en la prevención o el tratamiento de la lesión renal aguda | |
| JP2015516450A5 (hr) | ||
| JP2015516449A5 (hr) | ||
| EA202091127A1 (ru) | Фармацевтические композиции, включающие сафинамид |